WallStSmart

Lumentum Holdings Inc (LITE)vsCommScope Holding Company, Inc. (VISN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Lumentum Holdings Inc generates 9% more annual revenue ($2.11B vs $1.93B). VISN leads profitability with a 118.2% profit margin vs 11.9%. LITE appears more attractively valued with a PEG of 0.97. LITE earns a higher WallStSmart Score of 69/100 (B-).

LITE

Strong Buy

69

out of 100

Grade: B-

Growth: 7.3Profit: 6.5Value: 4.7Quality: 3.8
Piotroski: 4/9Altman Z: 0.58

VISN

Buy

58

out of 100

Grade: C

Growth: 5.3Profit: 7.0Value: 4.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

LITESignificantly Overvalued (-255.6%)

Margin of Safety

-255.6%

Fair Value

$161.46

Current Price

$777.17

$615.71 premium

UndervaluedFair: $161.46Overvalued
VISNSignificantly Overvalued (-153.9%)

Margin of Safety

-153.9%

Fair Value

$7.55

Current Price

$18.48

$10.93 premium

UndervaluedFair: $7.55Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LITE5 strengths · Avg: 9.2/10
Revenue GrowthGrowth
65.5%10/10

Revenue surging 65.5% year-over-year

EPS GrowthGrowth
71.1%10/10

Earnings expanding 71.1% YoY

Market CapQuality
$57.26B9/10

Large-cap with strong market position

Return on EquityProfitability
29.3%9/10

Every $100 of equity generates 29 in profit

PEG RatioValuation
0.978/10

Growing faster than its price suggests

VISN4 strengths · Avg: 9.0/10
Profit MarginProfitability
118.2%10/10

Keeps 118 of every $100 in revenue as profit

Revenue GrowthGrowth
50.6%10/10

Revenue surging 50.6% year-over-year

P/E RatioValuation
16.0x8/10

Attractively priced relative to earnings

Operating MarginProfitability
29.1%8/10

Strong operational efficiency at 29.1%

Areas to Watch

LITE3 concerns · Avg: 2.0/10
P/E RatioValuation
232.5x2/10

Premium valuation, high expectations priced in

Price/BookValuation
65.5x2/10

Trading at 65.5x book value

Altman Z-ScoreHealth
0.582/10

Distress zone — elevated risk

VISN3 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

PEG RatioValuation
2.942/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : LITE

The strongest argument for LITE centers on Revenue Growth, EPS Growth, Market Cap. Revenue growth of 65.5% demonstrates continued momentum. PEG of 0.97 suggests the stock is reasonably priced for its growth.

Bull Case : VISN

The strongest argument for VISN centers on Profit Margin, Revenue Growth, P/E Ratio. Profitability is solid with margins at 118.2% and operating margin at 29.1%. Revenue growth of 50.6% demonstrates continued momentum.

Bear Case : LITE

The primary concerns for LITE are P/E Ratio, Price/Book, Altman Z-Score. A P/E of 232.5x leaves little room for execution misses.

Bear Case : VISN

The primary concerns for VISN are EPS Growth, Return on Equity, PEG Ratio.

Key Dynamics to Monitor

VISN carries more volatility with a beta of 2.46 — expect wider price swings.

LITE is growing revenue faster at 65.5% — sustainability is the question.

VISN generates stronger free cash flow (256M), providing more financial flexibility.

Monitor COMMUNICATION EQUIPMENT industry trends, competitive dynamics, and regulatory changes.

Bottom Line

LITE scores higher overall (69/100 vs 58/100) and 65.5% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Lumentum Holdings Inc

TECHNOLOGY · COMMUNICATION EQUIPMENT · USA

Lumentum Holdings Inc. manufactures and sells optical and photonic products in the Americas, Asia-Pacific, Europe, the Middle East, and Africa. The company is headquartered in San Jose, California.

CommScope Holding Company, Inc.

TECHNOLOGY · COMMUNICATION EQUIPMENT · USA

Gyroscope Therapeutics Holdings plc, a clinical-stage gene therapy company, develops gene therapy products to treat patients with eye diseases. The company is headquartered in Stevenage, the United Kingdom.

Want to dig deeper into these stocks?